Novartis gene therapy approved, but will come at cost of more than $2M

Zolgensma is designed to be a cure for spinal muscular atrophy, but its steep price will pose difficulties for a system designed for chronic therapy rather than one-time treatments.

Source: Healthcare Dive, https://www.healthcaredive.com